New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV - press release
- Two-Year Resistance Analysis from CAPELLA Pivotal Trial Reinforces Sunlenca as a Person-Centered Option in Combination with an Optimized Background Regimen -
- Latest Research Highlights the Potential Impact of Lenacapavir on the Future of HIV Clinical Care -
October 20, 2023
